Rep. Gilbert Ray Cisneros, Jr. Sells Shares of AtriCure, Inc. (NASDAQ:ATRC)

Key Points

• Rep. Gilbert Ray Cisneros Jr. sold $1,001–$15,000 of AtriCure (ATRC) on September 29 in a Bank of America trust account. He also made multiple purchases and sales across healthcare, industrial, technology, and consumer stocks.
• AtriCure reported quarterly EPS of $0.18 and revenue of $153.6 million, exceeding analysts’ revenue expectations. The company issued fiscal 2026 EPS guidance of $0.24–$0.32.
• Analysts maintain a generally positive view, with seven Buy ratings and five Holds, an average “Moderate Buy” rating, and a consensus price target of $54.10; institutional investors own 99.11% of the stock.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of AtriCure, Inc. (NASDAQ:ATRC). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in AtriCure stock on September 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Alkermes NASDAQ: ALKS on 9/29/2026.

AtriCure Price Performance

ATRC stock opened at $56.87 on Wednesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $61.70. The firm's fifty day moving average is $51.69 and its 200 day moving average is $37.70. The firm has a market cap of $2.89 billion, a P/E ratio of 270.82 and a beta of 1.24.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The company had revenue of $153.60 million for the quarter, compared to analysts' expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter last year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Insider Activity at AtriCure

In other AtriCure news, Director Sven Wehrwein sold 25,000 shares of the firm's stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total value of $946,000.00. Following the completion of the sale, the director directly owned 40,518 shares in the company, valued at $1,533,201.12. This trade represents a 38.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Karl Dahlquist sold 9,370 shares of the company's stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the transaction, the insider owned 87,319 shares in the company, valued at $4,269,025.91. This trade represents a 9.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 74,868 shares of company stock valued at $3,317,897 over the last three months. Corporate insiders own 4.00% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ATRC shares. Weiss Ratings raised AtriCure from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Citigroup restated a "market outperform" rating on shares of AtriCure in a report on Tuesday, July 21st. Needham & Company LLC raised their price target on AtriCure from $45.00 to $64.00 and gave the stock a "buy" rating in a research report on Wednesday, September 2nd. Raymond James Financial set a $52.00 price target on AtriCure in a research report on Tuesday, July 21st. Finally, Stifel Nicolaus set a $65.00 price target on AtriCure in a research note on Thursday, September 17th. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $54.10.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in AtriCure during the 2nd quarter valued at $125,198,000. Bank of America Corp DE bought a new stake in shares of AtriCure during the 2nd quarter valued at about $24,465,000. Grandeur Peak Global Advisors LLC bought a new stake in shares of AtriCure during the 2nd quarter valued at about $16,435,000. Osterweis Capital Management Inc. bought a new stake in shares of AtriCure during the 2nd quarter valued at about $14,028,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of AtriCure during the second quarter valued at about $9,388,000. Hedge funds and other institutional investors own 99.11% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About AtriCure

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company's portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.